Co-Founder of Will and Way Consulting
Former CEO of MiNDFUL
J. O’Neal Johnston, Ph.D.
Founder and Chief Scientist of
Endocrine Associates, LLC
Meg Sanders is considered a thought leader in the legal cannabis movement and industry. She played a critical role in the development of regulations and policy in her home state of Colorado, where she was the only cannabis industry representative appointed by Colorado Governor John Hickenlooper to be involved in the creation of the regulated program as part of the Governor’s Task Force. From 2010 to 2017, Meg served as CEO of MiNDFUL, a vertically integrated cannabis business in Colorado specializing in cultivation, genetic preservation, medical and adult-use dispensary operations, and cannabis extraction.
Meg has been sought out by leading media outlets around the world including 60 Minutes, Rolling Stone, The New York Times, Le Monde, National Public Radio (NPR), NBC, The Wall Street Journal, BBC and many more. She has represented the cannabis industry as a board member of the Colorado Cannabis Chamber of Commerce and the Aurora (Colorado) Economic Development Council. Meg’s expertise has also been recognized and sought after by the National Science Academy, where she worked alongside representatives from the White House, FBI, and NSA to discuss cannabis as it relates to our bio-economy. She has been a featured speaker at Harvard Business School and has supported many local organizations in her hometown of Boulder, Colorado.
Today, Meg serves as the Co-Founder of Will and Way Consulting, a business formed to support teams eager to learn about opportunities that exist within newly formed medical marijuana programs. Will and Way Consulting is currently supporting efforts in numerous states including Maryland, Ohio, Florida, Arkansas, California, Tennessee and Massachusetts. Meg has also worked extensively with Clients in New York and Tennessee in the development of two hemp farms.
J. O’Neal Johnston, Ph.D.
Dr. Johnston is Founder and Chief Scientist of Endocrine Associates, LLC, a consulting group that specializes in endocrine related physiology, bio-molecular biology, pharmacology and oncology that serves the biomedical/pharmaceutical industries. Dr. Johnston bring a broad range of experiences to New World Health Brands with 38 years of biomedical research with bioactive natural product compounds and their analogs. Having an Animal Science background, he was trained in botany, microbiology, agronomy, nutrition, plant and animal sciences, then received his MS in Physiology & Genetics and Ph.D. in Biochemistry & Physiology. He initially worked in both Plant Sciences and Animal Genetics for the US Dept. of Agriculture, then pharmaceutical research at The Upjohn Company, William S. Merrell Company and Dow Chemical (Marion Merrell Dow Inc., later acquired by Sanofi, US). He held Adjunct Professorships in Environmental Health and Physiology at University of Cincinnati Medical School, subsequently serving as Director of Endocrinology for the Wood Hudson Cancer Research Laboratory.
Dr. Johnston has collaborated in development of 11 new chemical entities resulting in four marketed drugs. Responsible for discovery, development and clinical introduction of Plomestane, the first rationally-designed irreversible, enzyme-activated inhibitor of estrogen biosynthesis, a novel agent for treatment of breast cancer. This class of drugs (aromatase inhibitors) are the leading treatment choice worldwide for estrogen-dependent Breast Cancer in post-menopausal women.
Internationally recognized in the area of sterol biochemistry with extensive expertise in endocrinology, reproductive physiology, enzymology, and oncology. He is the Inventor of record on 27 U.S. patents and over 240 foreign patents. Author of six book chapters, 42 peer-reviewed journal articles, 148 presentations, including being an invited symposia speaker at 11 international conferences. Dr. Johnston was a peer review board member for seven scientific journals and grant reviewer of Regulatory Biology for National Science Foundation and for Biochemical Endocrinology Study Section, National Institutes of Health.